Fetal and maternal considerations in the management of stage I-B cervical cancer during pregnancy

https://doi.org/10.1016/0090-8258(89)90108-XGet rights and content

Abstract

The timing of treatment for stage I-B cervical carcinoma diagnosed during pregnancy is complicated by conflicting concerns for fetal survival and control of malignancy. There were 11 pregnant women with stage I-B cervical carcinoma diagnosed prior to fetal viability since 1969. Six patients were managed with termination of pregnancy and radical hysterectomy with pelvic lymphadenectomy. In 5 patients, treatment was delayed for 6 to 17 weeks and then delivery was accomplished by cesarean section followed directly by radical hysterectomy and pelvic lymphadenectomy. Two of the infants experienced complicated neonatal courses and would have benefited from additional delay. Benefits that could be achieved by delaying delivery for the fetus were calculated from a review of 600 inborn infants without congenital anomalies admitted to the neonatal intensive care (NICU) during 1984 and 1985. Neonatal mortality decreased from 32.8% at 26–27 weeks to 2.7% at 34–35 weeks gestation. Similar improvements in neonatal morbidity were demonstrated. Although adverse maternal outcomes were not associated with delay, an evaluation of risk cannot be derived from this series. Significant fetal benefit can accrue from relatively short delays in planned delivery dates. When stage I-B cervical carcinoma is diagnosed during pregnancy and when fetal survival is desired, delivery should be delayed to achieve fetal maturity, rather than only potential viability.

References (8)

There are more references available in the full text version of this article.

Cited by (71)

  • Cancer in pregnancy

    2023, DiSaia and Creasman Clinical Gynecologic Oncology
  • Cancer in pregnancy

    2018, Clinical Gynecologic Oncology
  • Management and outcome of cervical cancer diagnosed in pregnancy

    2017, American Journal of Obstetrics and Gynecology
    Citation Excerpt :

    While the pregnant patients had a significantly longer delay from diagnosis to treatment, this did not seem to impact the overall oncologic outcome. In this setting, it may be reasonable to consider delaying delivery until at least 37 weeks’ gestation, if not 39 weeks, due to increasing pediatric literature about the risks of late preterm and early term birth.21-24 Many current studies of cervical cancer management in the context of pregnancy describe iatrogenic preterm birth to expedite maternal oncologic treatment.10,21,25

  • Cancer in Pregnancy

    2012, Clinical Gynecologic Oncology: Eighth Edition
  • Recurrence during pregnancy of a conservatively treated early-stage cervical squamous cell carcinoma

    2011, Fertility and Sterility
    Citation Excerpt :

    Adenocarcinoma was diagnosed at the beginning of pregnancy, and medical abortion was performed at 9 weeks. Although there are few available data on this subject in the literature, pregnancy does not appear to worsen the prognosis of cervical cancer in its early stages (13–17). Finally, it is important to note that recurrence is encountered even after nonconservative management of cervical tumors (5, 6).

View all citing articles on Scopus

Presented at the Annual Meeting of The Western Association of Gynecologic Oncologists, May 13–16, 1987.

View full text